Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19316660 | 0.86 | PTPN1 (0.46) | ADRB2ADRB1ADRB3PTPN1SERPINE1 | |
| SCHEMBL19316662 | 0.85 | PTPN1 (0.45) | ADRB2ADRB1ADRB3PTPN1SERPINE1 | |
| SCHEMBL19316658 | 0.83 | ADRB2 (0.54) | ADRB2ADRB1ADRB3 | |
| SCHEMBL21422411 | 0.82 | ADRB2 (0.41) | ADRB2ADRB1ADRB3PTPN1SERPINE1 | |
| SCHEMBL19316643 | 0.82 | PTPN1 (0.42) | ADRB2ADRB1ADRB3PTPN1SERPINE1 | |
| SCHEMBL21422479 | 0.79 | ADRB2 (0.37) | ADRB2ADRB1ADRB3PTPN1SERPINE1 | |
| SCHEMBL13135914 | 0.79 | ADRB2 (0.62) | ADRB2ADRB1ADRB3 | |
| SCHEMBL19316648 | 0.78 | ADRB2 (0.36) | ADRB2ADRB1ADRB3PTPN1PRKCA | |
| SCHEMBL19316664 | 0.77 | ADRB2 (0.38) | ADRB2ADRB1ADRB3PRKCA | |
| SCHEMBL13135915 | 0.77 | ADRB2 (0.60) | ADRB2ADRB1ADRB3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | H1-0, VMP1, CHRM1 | ADRB2 735/4885ADRB1 850/4885ADRB3 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.